Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $27,381 - $30,617
-473 Reduced 11.68%
3,575 $207,000
Q1 2023

May 04, 2023

SELL
$65.71 - $74.53 $82,991 - $94,131
-1,263 Reduced 23.78%
4,048 $280,000
Q4 2022

Feb 06, 2023

BUY
$68.48 - $81.09 $68,137 - $80,684
995 Added 23.05%
5,311 $382,000
Q3 2022

Nov 09, 2022

BUY
$0.13 - $76.84 $12 - $7,530
98 Added 2.32%
4,316 $307,000
Q2 2022

Aug 08, 2022

SELL
$72.62 - $79.98 $2,323 - $2,559
-32 Reduced 0.75%
4,218 $325,000
Q1 2022

May 12, 2022

SELL
$61.48 - $73.72 $8,545 - $10,247
-139 Reduced 3.17%
4,250 $310,000
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $42,206 - $49,203
787 Added 21.85%
4,389 $274,000
Q3 2021

Oct 26, 2021

SELL
$59.17 - $69.31 $17,751 - $20,793
-300 Reduced 7.69%
3,602 $213,000
Q2 2021

Aug 12, 2021

SELL
$61.91 - $67.42 $85,311 - $92,904
-1,378 Reduced 26.1%
3,902 $261,000
Q1 2021

May 12, 2021

BUY
$59.34 - $66.74 $53,109 - $59,732
895 Added 20.41%
5,280 $327,000
Q4 2020

Feb 11, 2021

SELL
$57.74 - $65.43 $9,527 - $10,795
-165 Reduced 3.63%
4,385 $283,000
Q3 2020

Nov 13, 2020

SELL
$57.43 - $63.64 $5,053 - $5,600
-88 Reduced 1.9%
4,550 $290,000
Q1 2020

May 15, 2020

SELL
$46.4 - $67.43 $54,102 - $78,623
-1,166 Reduced 20.09%
4,638 $283,000
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $11,170 - $14,571
227 Added 4.07%
5,804 $389,000
Q3 2019

Nov 20, 2019

BUY
$42.77 - $50.71 $238,528 - $282,809
5,577 New
5,577 $328,000
Q1 2019

May 16, 2019

SELL
$45.12 - $53.8 $263,726 - $314,461
-5,845 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$48.76 - $63.23 $285,002 - $369,579
5,845 New
5,845 $304,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Full Sail Capital, LLC Portfolio

Follow Full Sail Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Full Sail Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Full Sail Capital, LLC with notifications on news.